Chan Ramony, Dear Blake F, Titov Nick, Chow Josephine, Suranyi Michael
Renal Unit, Liverpool Hospital, Sydney, Australia; Consultation Liaison Psychiatry, Liverpool Hospital, Sydney, Australia; The University of New South Wales, Sydney, Australia.
eCentreClinic, Department of Psychology, Macquarie University, Sydney, Australia.
J Psychosom Res. 2016 Oct;89:78-84. doi: 10.1016/j.jpsychores.2016.08.012. Epub 2016 Aug 29.
Treating depression among patients with chronic kidney disease (CKD) is imperative because of its high prevalence and health-related costs. However, many patients with CKD experience significant barriers to effective face-to-face psychological treatments. Internet-delivered cognitive behaviour therapy (iCBT) may help overcome the treatment barriers. The aim of the present study was to explore the acceptability and preliminary efficacy of iCBT for depression and anxiety among patients with CKD on haemodialysis.
A single-group open trial design involving 22 patients on dialysis and an established iCBT treatment for anxiety and depression was employed. The primary outcomes were symptoms of depression, anxiety and general psychological distress. The secondary and tertiary outcomes were disability, quality of life, kidney disease-related loss and kidney disease burden. A generalised estimation equation modelling technique was employed.
Clinically significant improvements (avg. % of improvement) were observed in the primary outcomes of depression (34%), anxiety (31%) and general distress (26%), which were maintained or further improved to 3-month follow-up. Improvements were also observed for quality of life (12%) and kidney disease-related loss (30%). However, no improvements in disability and kidney disease burden were found. High levels of acceptability were reported and relatively little clinician time (99.45min; SD=14.61) was needed to provide the treatment.
The present results provide encouraging support for the potential of iCBT as an innovative way of increasing access to effective psychological treatment for CKD patients. These results provide much needed support for further research in this area.
Australian and New Zealand Clinical Trials Registry: ACTRN12613000103763.
慢性肾脏病(CKD)患者中抑郁症患病率高且与健康相关的成本高昂,因此治疗该类患者的抑郁症势在必行。然而,许多CKD患者在接受有效的面对面心理治疗时面临重大障碍。基于互联网的认知行为疗法(iCBT)可能有助于克服这些治疗障碍。本研究的目的是探讨iCBT对接受血液透析的CKD患者抑郁症和焦虑症的可接受性及初步疗效。
采用单组开放试验设计,纳入22例透析患者,并采用既定的iCBT治疗焦虑症和抑郁症。主要结局为抑郁、焦虑和一般心理困扰症状。次要和三级结局为残疾、生活质量、肾脏病相关损失和肾脏病负担。采用广义估计方程建模技术。
在抑郁(34%)、焦虑(31%)和一般困扰(26%)的主要结局中观察到具有临床意义的改善(平均改善百分比),这些改善在3个月随访时得以维持或进一步改善。生活质量(12%)和肾脏病相关损失(30%)也有改善。然而,在残疾和肾脏病负担方面未发现改善。报告显示iCBT的可接受性较高,提供该治疗所需的临床医生时间相对较少(99.45分钟;标准差=14.61)。
本研究结果为iCBT作为增加CKD患者获得有效心理治疗途径的创新方法的潜力提供了令人鼓舞的支持。这些结果为该领域的进一步研究提供了急需的支持。
澳大利亚和新西兰临床试验注册中心:ACTRN12613000103763。